Item 8.01 Other Events.
As previously disclosed in our Current Report on Form 8-K filed with the U.S.
Securities and Exchange Commission (the "SEC") on August 10, 2021, Intersect
ENT, Inc., a Delaware corporation (the "Company" or "Intersect"), entered into
an Agreement and Plan of Merger, dated August 6, 2021 (the "Merger Agreement"),
with Medtronic, Inc., a Minnesota corporation ("Parent"), and Project Kraken
Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent
("Merger Sub"), pursuant to which, among other things, Merger Sub will merge
with and into the Company, in accordance with the General Corporation Law of the
State of Delaware, with the Company continuing as the surviving corporation (the
"Surviving Corporation") and as a wholly-owned subsidiary of Parent (the
"Merger").
On May 9, 2022, the U.S. Federal Trade Commission granted early termination of
the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 ("HSR Act") with respect to the Merger. With early termination granted
under the HSR Act, the transaction has now received all applicable antitrust
regulatory approvals.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
INTERSECT ENT, INC. 
